Objectives: The objective of this study is the exploration of Artificial Intelligence and Natural Language Processing techniques to support the automatic assignment of the four Response Evaluation Criteria in Solid Tumors (RECIST) scales based on radiology reports. We also aim at evaluating how languages and institutional specificities of Swiss teaching hospitals are likely to affect the quality of the classification in French and German languages.

Methods: In our approach, 7 machine learning methods were evaluated to establish a strong baseline. Then, robust models were built, fine-tuned according to the language (French and German), and compared with the expert annotation.

Results: The best strategies yield average F1-scores of 90% and 86% respectively for the 2-classes (Progressive/Non-progressive) and the 4-classes (Progressive Disease, Stable Disease, Partial Response, Complete Response) RECIST classification tasks.

Conclusions: These results are competitive with the manual labeling as measured by Matthew's correlation coefficient and Cohen's Kappa (79% and 76%). On this basis, we confirm the capacity of specific models to generalize on new unseen data and we assess the impact of using Pre-trained Language Models (PLMs) on the accuracy of the classifiers.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303934PMC
http://dx.doi.org/10.3389/fdgth.2023.1195017DOI Listing

Publication Analysis

Top Keywords

recist classification
8
radiology reports
8
french german
8
multilingual recist
4
classification radiology
4
reports supervised
4
supervised learning
4
learning objectives
4
objectives objective
4
objective study
4

Similar Publications

Importance: Progressive disease (PD) in patients treated with immune checkpoint inhibitors (ICIs) varies widely in outcomes according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Efforts to modify RECIST for ICI treatment have not resolved the heterogeneity in PD patterns, posing a clinical challenge.

View Article and Find Full Text PDF

Background: Immunotherapy is an emerging treatment modality for clear cell renal cell carcinoma (CCRCC). As a molecule involved in the prognosis of CCRCC, the effect of complement C3a expression levels on immunotherapy is unclear. This study aims to investigate the correlation between C3a and clinicopathological features in early CCRCC, as well as the alterations in complement C3a during immunotherapy for advanced CCRCC and its influence on therapeutic outcomes.

View Article and Find Full Text PDF

Deep learning for oncologic treatment outcomes and endpoints evaluation from CT scans in liver cancer.

NPJ Precis Oncol

November 2024

Department of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.

Article Synopsis
  • Accurate treatment response assessment using serial CT scans is crucial for cancer clinical trials, but the current method (RECIST guideline) can be subjective and imprecise, especially for multifocal liver cancer lesions.
  • The newly developed RECORD system utilizes deep learning to objectively evaluate treatment responses, segment liver tumors, and provide classifications based on tumor volume analysis, achieving high accuracy in assessments across multiple studies.
  • RECORD outperforms traditional methods by correlating strongly with clinical evaluations and effectively stratifying patient risks, suggesting a need for future research to apply this technology to other types of cancer.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to explore how tumor size affects the prognosis of patients with metastatic renal cell carcinoma (mRCC) receiving two different treatment approaches: dual immune checkpoint inhibitors (IOIO) and a combination of immune checkpoint inhibitors with tyrosine kinase inhibitors (IOTKI).
  • Researchers analyzed data from 180 mRCC patients to evaluate the impact of tumor size on progression-free survival (PFS) and overall survival (OS), finding that it was a significant predictor especially in the IOIO group.
  • The results suggest that tumor size should be prioritized in treatment decisions for renal cancer, particularly for patients undergoing IOIO therapy, as it offered better prognostic insights than other factors like nephrectomy status and IMDC risk classification
View Article and Find Full Text PDF

In anticancer research, tumor growth measured in mouse models is important for assessing treatment efficacy for a treatment to progress to human clinical trials. Statistical analysis of time-to-event tumor volume data is complex because of heterogeneity in response and welfare-related data loss. Traditional statistical methods of testing the mean difference between groups are not robust because they assume common responses across a population.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!